Platform
Company
Immunology & Autoimmune
Review status
Currently under review
Pending specialist review and validation.
The DRVVT Confirm Preliminary test is part of the evaluation for lupus anticoagulant, an antibody that interferes with phospholipid-dependent steps in blood clotting. It repeats the dilute Russell viper venom clotting assay in the presence of added phospholipid to check whether a prolonged clotting time improves when extra phospholipid is available.
By comparing this confirm step with the initial screen, the laboratory can see whether the pattern fits a phospholipid-dependent inhibitor such as a lupus anticoagulant. The preliminary label indicates you are seeing an early analytical result that may be updated when the full panel of tests and expert review are completed.
Healthcare providers order this test when there is concern for a lupus anticoagulant, such as after an unexplained prolonged clotting test, a history of blood clots, or certain pregnancy complications. The confirm step helps distinguish true phospholipid-dependent inhibitors from other causes of abnormal clotting times, improving the accuracy of the overall assessment.
Results contribute to the evaluation for antiphospholipid syndrome, help guide decisions about anticoagulation, and support planning for procedures where bleeding and clotting risks must be balanced. This test is usually interpreted together with the DRVVT screen, mixing studies, and antiphospholipid antibody tests to provide a complete picture.
If the confirm result looks consistent with a normal pattern, a lupus anticoagulant is less likely. If it remains abnormal compared with the screen, the pattern suggests a phospholipid-dependent inhibitor. Your clinician will put these findings together with other laboratory tests and your medical history before drawing conclusions.
Medicines and clinical conditions can interfere with this assay, so an unexpected result may need repeat testing once interfering factors are addressed. A single positive result does not by itself diagnose antiphospholipid syndrome. Your care team may recommend follow-up testing and correlation with other results before making treatment decisions.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Direct oral anticoagulants, heparin, and warfarin can affect clot-based assays and may cause misleading results. Tell your care team about all blood thinners so the lab can account for them or schedule testing appropriately.
Active thrombosis, infection, or systemic inflammation can alter clotting tests and transiently produce lupus anticoagulant patterns. Testing may be repeated after you are clinically stable.
Improper fill volume, delayed processing, or significant hemolysis, lipemia, or icterus can interfere with assay performance. Proper collection in citrate tubes and timely processing improve reliability.
Pregnancy, postpartum changes, and estrogen therapy can influence coagulation and antiphospholipid testing. Your clinician will interpret results in the context of these physiologic changes.
Lupus anticoagulant can appear temporarily with certain infections or after some medications. Persistently positive results on separate occasions are more clinically meaningful.
Deficiencies or inhibitors of clotting factors, and very high C-reactive protein, can prolong clotting independently of lupus anticoagulant. Additional tests help sort out these possibilities.
References